Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 5/20 | 0.41 |
| ▸ | CTSS | P25774 | 2/20 | 0.40 |
| ▸ | CTSK | P43235 | 2/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.39 |
| ▸ | JAK2 | O60674 | 2/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.36 |
| ▸ | BCL2 | P10415 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28605926 | 0.87 | MEN1 (0.46) | IDO1CTSSCTSKGPR119CYP17A1 | |
| SCHEMBL28920291 | 0.86 | IDO1 (0.41) | IDO1CTSSCTSKGPR119CYP17A1 | |
| SCHEMBL22125838 | 0.86 | IDO1 (0.41) | IDO1CTSSCTSKGPR119CYP17A1 | |
| SCHEMBL28618419 | 0.84 | CTSS (0.47) | IDO1CTSSCTSKGPR119CYP17A1 | |
| SCHEMBL24454248 | 0.83 | IDO1 (0.40) | IDO1GPR119CYP17A1JAK2MEN1 | |
| SCHEMBL28919658 | 0.83 | MEN1 (0.42) | IDO1CTSSCTSKCYP17A1JAK2 | |
| SCHEMBL28609015 | 0.82 | HDAC8 (0.53) | CTSSCTSKSCN9ABCL2 | |
| SCHEMBL29894942 | 0.82 | JAK2 (0.40) | CTSSCTSKCYP17A1JAK2SCN9A | |
| SCHEMBL30231080 | 0.82 | CTSS (0.42) | CTSSCTSKCYP17A1JAK2MEN1 | |
| SCHEMBL30230958 | 0.81 | CTSS (0.41) | CTSSCTSKCYP17A1JAK2SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11377425-B1 | Small molecule modulators of IL-17 | LEO PHARMA A/S (DK) | 2022-07-05 | — | — | US | disclosed |
| CN-113164448-A | Amino acid anilines as small molecule modulators of IL-17 | 利奥制药有限公司 | 2021-07-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11377425-B1 | Small molecule modulators of IL-17 | IL17A, IL15, IL2 | IDO1 594/4885CTSS 757/4885CTSK 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.